Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of unusually large options trading on Wednesday. Stock traders purchased 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the typical volume of 53 put options.

Analyst Upgrades and Downgrades

MRVI has been the topic of a number of research reports. Wall Street Zen raised shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Wells Fargo & Company lifted their target price on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.86.

Hedge Funds Weigh In On Maravai LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sprott Inc. acquired a new position in shares of Maravai LifeSciences in the 3rd quarter valued at $29,000. Virtu Financial LLC acquired a new stake in shares of Maravai LifeSciences during the 4th quarter worth $34,000. Insigneo Advisory Services LLC acquired a new stake in shares of Maravai LifeSciences during the 4th quarter worth $34,000. Quantessence Capital LLC purchased a new position in shares of Maravai LifeSciences in the 3rd quarter worth $31,000. Finally, Stifel Financial Corp purchased a new position in shares of Maravai LifeSciences in the 4th quarter worth $36,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Down 2.2%

Shares of NASDAQ:MRVI opened at $3.05 on Thursday. The stock’s 50-day moving average price is $3.44 and its two-hundred day moving average price is $3.29. The company has a current ratio of 6.60, a quick ratio of 5.69 and a debt-to-equity ratio of 0.85. Maravai LifeSciences has a 12-month low of $1.66 and a 12-month high of $4.11. The firm has a market cap of $779.92 million, a price-to-earnings ratio of -3.39 and a beta of 0.38.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. The company had revenue of $49.87 million during the quarter, compared to the consensus estimate of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. On average, research analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.